FTC re­view pe­ri­ods end for Ab­b­Vie-Im­muno­Gen $10.1B deal and $4B BMS-Rayze­Bio buy­out

Ab­b­Vie moved ahead with its $10.1 bil­lion ac­qui­si­tion of an­ti­body-drug con­ju­gate biotech Im­muno­Gen, while Bris­tol My­ers Squibb’s big ac­qui­si­tion of ra­dio­phar­ma­ceu­ti­cals biotech Rayze­Bio is like­ly on the way too, de­spite the Fed­er­al Trade Com­mis­sion’s height­ened at­ten­tion on phar­ma M&A.

Ab­b­Vie an­nounced the clo­sure of its buy on Mon­day, sev­er­al days af­ter the end of the wait­ing pe­ri­od for the FTC. The 30-day wait­ing pe­ri­od un­der the Hart-Scott-Rodi­no An­titrust Im­prove­ments Act (HSR Act) al­lowed the FTC to ob­ject to the Ab­b­Vie-Im­muno­Gen propo­si­tion un­til Feb. 7.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA